GSA Capital Partners LLP Has $996,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Key Points

• GSA Capital Partners LLP increased its stake in Verve Therapeutics by 56.6%, acquiring an additional 78,768 shares for a total of 217,927 shares.
• Analysts have given mixed ratings for Verve Therapeutics, with a consensus rating of "Hold" and an average price target of $14.57, following recent downgrades from some firms.
• Verve Therapeutics reported quarterly earnings of ($0.35) per share, surpassing expectations, with revenue of $32.98 million, significantly above the forecast of $7.13 million.

GSA Capital Partners LLP lifted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 56.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 217,927 shares of the company's stock after purchasing an additional 78,768 shares during the period. GSA Capital Partners LLP owned 0.24% of Verve Therapeutics worth $996,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. BVF Inc. IL increased its position in shares of Verve Therapeutics by 962.2% during the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock valued at $38,939,000 after purchasing an additional 6,254,050 shares during the period. Point72 Asset Management L.P. bought a new stake in Verve Therapeutics in the fourth quarter valued at $7,863,000. Schonfeld Strategic Advisors LLC raised its stake in Verve Therapeutics by 57.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock worth $21,372,000 after acquiring an additional 1,382,176 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Verve Therapeutics during the fourth quarter valued at $1,643,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Verve Therapeutics by 18.5% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company's stock valued at $10,423,000 after purchasing an additional 288,678 shares in the last quarter. 97.11% of the stock is currently owned by institutional investors.

Verve Therapeutics Price Performance

Shares of VERV stock remained flat at $11.13 during trading hours on Tuesday. The firm has a market capitalization of $992.13 million, a P/E ratio of -5.27 and a beta of 2.23. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $11.40. The company has a 50-day moving average of $9.43 and a 200 day moving average of $7.06.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. The company had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. As a group, equities research analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VERV has been the topic of a number of research analyst reports. Jefferies Financial Group lowered Verve Therapeutics from a "buy" rating to a "hold" rating and decreased their price target for the stock from $28.00 to $11.00 in a research report on Wednesday, June 18th. BMO Capital Markets reaffirmed a "market perform" rating and issued a $13.50 price target (down from $20.00) on shares of Verve Therapeutics in a report on Friday, June 27th. William Blair lowered shares of Verve Therapeutics from a "strong-buy" rating to a "market perform" rating in a report on Tuesday, June 17th. Canaccord Genuity Group downgraded shares of Verve Therapeutics from a "strong-buy" rating to a "hold" rating and dropped their target price for the stock from $39.00 to $13.00 in a research note on Tuesday, June 17th. Finally, Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $14.57.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.